Skip to content

Immunomodulation Effect of Regional Citrate Anticoagulation in Acute Kidney Injury Requiring Continuous Renal Replacement Therapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02423642
Enrollment
30
Registered
2015-04-22
Start date
2013-07-31
Completion date
2014-11-30
Last updated
2021-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

Acute Kidney Injury Requiring Continuous Renal Replacement Therapy

Brief summary

The purpose of this study is to study the effect of anticoagulation in immune response with Acute Kidney Injury (AKI) undergoing Continuous Renal Replacement Therapy (CRRT).

Interventions

CRRT with anticoagulant : regional citrate anticoagulation Filter : AQUAMAX™ (Edwards Lifesciences)

PROCEDUREContinuous renal replacement therapy with no anticoagulation or heparin

CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Systemic inflammatory response syndrome; SIRS \> or = 2 meets definition * Patients with acute kidney injury in the intensive care ward. * Requiring continuous renal replacement therapy.

Exclusion criteria

* Pregnancy * Cirrhosis * End stage renal disease * HIV infection * Serum creatinine in male \> 2 mg/dl and female \> 1.5 mg/dl * Bleeding

Design outcomes

Primary

MeasureTime frameDescription
Functions of inflammatory cells24 hoursCD11b expression on PMN and HLA-DR expression on monocyte
Regulation of inflammatory reactions and and opsonization in microorganisms24 hoursC3a and C5a
Activity of acute phase protein during acute inflammation24 hoursPAI-1

Secondary

MeasureTime frame
survival rate28 days
length of ICU stay28 days

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026